- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about edit
Recent news which mentions edit
Earnings Scheduled For November 3, 2023
November 03, 2023
From Benzinga
Sent Your Boss The Message Meant For Your Girlfriend On Instagram — Now You Can Save Your Bacon
November 01, 2023
From Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
From Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
From Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
October 18, 2023
From Motley Fool
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
From Benzinga
From InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
October 17, 2023
From Benzinga
Tickers
EDIT
From Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
October 02, 2023
From Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
From Benzinga
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
From Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
From Benzinga
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
September 29, 2023
From Benzinga
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
From Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
From Benzinga
1 Gene Editing Stock to Buy Now, and 1 to Sell
September 23, 2023
From Motley Fool
From Motley Fool
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
June 29, 2023
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.